Drugs / Eletriptan
Eletriptan
also known as
Eletriptan HBr · Eletriptan hydrobromide · NSC-759258 · RELPAX · UK-116,044 · UK-116,044-04 · UK-116,044-04 FREE BASE
Small molecule targets HTR1B, HTR1D, HTR1F via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | RELPAX | — | 2002-12-26 | fda.gov ↗ |
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01139515 | Jul 2010 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06677229 | Aug 2025 → Dec 2026 expected | spinal cord injury | Technophage, SA | Recruiting | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT00385008 | Sep → Nov 2006 | migraine disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01859481 | Mar 2000 → Mar 2002 | migraine with aura, migraine without aura | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01989936 | Jan 1999 → Sep 2000 | migraine disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01986270 | Dec 1996 → Jan 1998 | migraine disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01986088 | Nov 1996 → Jan 1998 | migraine disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01978496 | Jul 1996 → Dec 1997 | migraine disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT00174395 | Mar 2005 → Oct 2006 | migraine disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00259649 | Aug 2004 → Aug 2008 | migraine disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00632385 | Jan → Aug 2003 | migraine disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00634985 | Nov 2002 → Dec 2003 | migraine disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01276977 | Apr 2008 → Dec 2010 | migraine disorder | California Medical Clinic for Headache | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00871806 Comparator | Apr 2009 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00751803 Comparator | Aug 2008 → May 2009 | migraine disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT01086358 Comparator | Sep 2009 → Aug 2016 | — | The Cleveland Clinic | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eletriptan | “The study will evaluate whether the blood concentrations of eletriptan administered using two test formulations of oral disintegrating tablets are comparable to those observed...” NCT00871806 ↗15“Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan” NCT01086358 ↗ “Eletriptan 40 mg tablet” NCT01276977 ↗ |
| Known as | Eletriptan HBr | “Oral administration of Eletriptan HBr in the form of tablets, 40 mg once daily (q.d.) for a total of 6 days, together with their usual SOC treatment.” NCT06677229 ↗ |
| Known as | Eletriptan hydrobromide | “Eletriptan hydrobromide (HBr) is a second-generation serotonin (5-HT) receptor agonist with high affinity for 5-HT1B, 5-HT1D and 5-HT1F receptors approved for the acute...” NCT06677229 ↗ |
| Known as | NSC-759258 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1510 ↗ |
| Known as | RELPAX | “RELPAX(eletriptan) 40mg Tablet” NCT00385008 ↗ |
| Known as | UK-116,044 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1510 ↗ |
| Known as | UK-116,044-04 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1510 ↗ |
| Known as | UK-116,044-04 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1510 ↗ |
| Action | Activate | “Serotonin 1f (5-HT1f) receptor agonist” CHEMBL1510 ↗2“Serotonin 1b (5-HT1b) receptor agonist” CHEMBL1510 ↗ “Serotonin 1d (5-HT1d) receptor agonist” CHEMBL1510 ↗ |
| Modality | Small molecule | — CHEMBL1510 ↗ |
| Route | Oral | “oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days” NCT00259649 ↗ |
| Target | HTR1B | “Serotonin 1b (5-HT1b) receptor agonist” CHEMBL1510 ↗ |
| Target | HTR1D | “Serotonin 1d (5-HT1d) receptor agonist” CHEMBL1510 ↗ |
| Target | HTR1F | “Serotonin 1f (5-HT1f) receptor agonist” CHEMBL1510 ↗ |